Fulcrum Therapeutics, Inc. (FULC) stock
FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.77+0.09 (+2.45%)
Close on Nov 13, 2026Market cap $287.64MP/E –Yield –
Fulcrum Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Fulcrum Therapeutics's profit margin for the twelve months ending Dec 31, 2024 was -12.2%. For fiscal 2024 it was -12.2%, against -3470.1% the year before. The highest annual figure on record is -12.2% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -12.2% | +3457.9 |
| FY2023 | Dec 31, 2023 | -3470.1% | −1737.6 |
| FY2022 | Dec 31, 2022 | -1732.4% | −1310.5 |
| FY2021 | Dec 31, 2021 | -421.9% | +380.8 |
| FY2020 | Dec 31, 2020 | -802.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2024 | Jun 30, 2024 | 69.3% | +8468.9 |
| Q4 FY2023 | Dec 31, 2023 | -2842.3% | +973.1 |
| Q3 FY2023 | Sep 30, 2023 | -3164.3% | −1157.7 |
| Q2 FY2023 | Jun 30, 2023 | -2702.6% | −892.3 |
| Q1 FY2023 | Mar 31, 2023 | -8399.7% | −7399.4 |
| Q4 FY2022 | Dec 31, 2022 | -3815.3% | −3608.7 |
| Q3 FY2022 | Sep 30, 2022 | -2006.6% | −1586.8 |
| Q2 FY2022 | Jun 30, 2022 | -1810.3% | −1361.8 |
| Q1 FY2022 | Mar 31, 2022 | -1000.3% | −645.3 |
| Q4 FY2021 | Dec 31, 2021 | -206.7% | +212.7 |
| Q3 FY2021 | Sep 30, 2021 | -419.8% | +606.3 |
| Q2 FY2021 | Jun 30, 2021 | -448.5% | +335.8 |
| Q1 FY2021 | Mar 31, 2021 | -355.0% | +2105.3 |
| Q4 FY2020 | Dec 31, 2020 | -419.4% | – |
| Q3 FY2020 | Sep 30, 2020 | -1026.1% | – |
| Q2 FY2020 | Jun 30, 2020 | -784.3% | – |
| Q1 FY2020 | Mar 31, 2020 | -2460.3% | – |
See a number that looks wrong?